CODA: COvid and Diabetes Assessment
CODA:新冠肺炎和糖尿病评估
基本信息
- 批准号:10755899
- 负责人:
- 金额:$ 599.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-21 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAdultAmericanAntibodiesAreaBeta CellBiological MarkersBiological ProcessBlood VesselsCDC42 geneCOVID-19COVID-19 diagnosisCOVID-19 impactCOVID-19 pandemicCOVID-19 patientCOVID-19 surveillanceCOVID-19 testCOVID-19 treatmentCell physiologyCessation of lifeChildChildhoodChildhood diabetesClinicalClinical ResearchConsentDataDeteriorationDevelopmentDiabetes MellitusDiagnosisElectronic Health RecordEnvironmental Risk FactorEpidemiologyFamilyFibrosisFundingFutureGenomicsGlucose tolerance testHealthHealth Services ResearchHealth systemIndividualInfectionInflammationInformaticsInfrastructureInsulin ResistanceInsulin-Dependent Diabetes MellitusInternetInterventionIntervention StudiesLinkLong COVIDMetabolicMulticenter TrialsNon-Insulin-Dependent Diabetes MellitusNucleocapsidObesityObservational StudyOutcomeOutpatientsParticipantPatientsPhysiologicalPhysiologyPopulationPost-Acute Sequelae of SARS-CoV-2 InfectionProcessPublic HealthRecordsRegistriesResearchResourcesRiskRoleSARS-CoV-2 exposureSARS-CoV-2 infectionSARS-CoV-2 negativeSerology testSiteStandardizationStructureStudy SubjectSurveysTelephoneTestingThrombophiliaTimeUnited States National Institutes of HealthWorkcohortcommunity engagementcoronavirus diseasedata hubdrug repurposingelectronic health dataepidemiology studyexperienceglycemic controlimprovedmembermetabolomicspandemic diseasepatient orientedpatient portalpatient registrypatient subsetsrecruitsocialtype 2 diabetes in childrentype I and type II diabetes
项目摘要
Project Summary
Several studies have found that infection with SARS-CoV-2 and COVID-19 diagnosis are associated with the
development and progression of both Type 1 (T1D) and Type 2 Diabetes (T2D), possibly through infection of
beta cells, increased insulin resistance, increased inflammation and fibrosis, and other biological processes.
The proposed study will take advantage of robust existing infrastructure to rapidly identify, recruit, and retain
diverse cohorts of English and Spanish speaking pediatric and adult patients with recently diagnosed T1D or
T2D. The study will include 1600 study participants diagnosed with diabetes in the last 3 months, who have
had a known COVID-19 infection in the past 90 days and those with recent diagnosis of diabetes and no
known COVID-19 infection in the past year. The study will leverage PCORnet, a unique national network of
over 60 health systems with electronic health record (EHR) data on over 80 million patients and a track record
for successful study recruitment. We will query EHR records to swiftly identify potential study subjects with
recent diagnosis of diabetes and contact them via patient portals, telephone, face-to-face encounters, and
other approaches. We will also leverage the T1D Exchange (T1DX), a national network of 54 diabetes centers
and an online patient registry of 17,000 individuals with T1D. Consented participants will partake in regular
web/mobile or telephone surveys leveraging a previously developed REDCap/Twilio platform. Participants will
also come to sites for regular serological testing, and a subsample will participate in more robust testing of
glucose tolerance, biomarkers, and vascular function. This data will be supplemented by longitudinal EHR data
from participating sites and across PCORnet. Participants will be followed for 2 years. Aim 1 will examine if
patients with recent T2D who have recent COVID-19 are more likely to have worse glycemic control, increased
inflammation and increased insulin resistance than patients without recent COVID-19. Aim 2 will examine if
patients with recent T1D who have recent COVID-19 are more likely to have worse glycemic control, increased
inflammation and more rapid reduction in beta cell function than patients without recent COVID-19. Aim 3 will
evaluate a subset of patients with diabetes to examine if COVID-19 is associated with worse vascular function,
increased inflammation and hypercoagulability. Aim 4 will explore the role of genomic/social/environmental
factors on inflammation and metabolic function. Aim 5 will leverage EHR data to explore the role of COVID-19
and COVID-19 treatments on diabetes development and diabetes-related outcomes across the pandemic. The
study will be led by a team with significant experience related to COVID-19, post-acute sequelae of COVID-19
(PASC), obesity and diabetes in children and adults, epidemiological research, informatics, health services
research, genomics, metabolomics, physiology, patient and family engagement and other areas. The proposed
work will provide a deeper understanding of the relationship between COVID-19 and diabetes, that can support
future interventions and public health approaches to improve health.
项目摘要
多项研究发现,感染SARS-CoV-2和诊断为新冠肺炎与
1型糖尿病(T1D)和2型糖尿病(T2D)的发生和发展,可能是通过感染
β细胞,胰岛素抵抗增加,炎症和纤维化增加,以及其他生物过程。
拟议的研究将利用强大的现有基础设施来快速识别、招聘和保留
新近诊断为T1D或T1D的儿童和成人患者中讲英语和西班牙语的不同队列
T2D。这项研究将包括1600名在过去3个月内被诊断为糖尿病的研究参与者,他们有
在过去90天内已知感染新冠肺炎的患者以及最近诊断为糖尿病和无糖尿病的患者
已知在过去一年感染新冠肺炎。这项研究将利用PCORnet,一个独特的全国性网络
60多个医疗系统,具有8000多万名患者的电子健康记录(EHR)数据和跟踪记录
为了成功的招生。我们将查询电子病历记录,以快速识别潜在的研究对象
最近诊断出的糖尿病,并通过患者门户网站、电话、面对面接触和
其他方法。我们还将利用T1D交易所(T1DX),这是一个由54个糖尿病中心组成的全国性网络
以及17,000名患有T1D的在线患者登记。经同意的参与者将定期参加
利用以前开发的RedCap/Twilio平台进行网络/移动或电话调查。参与者将
也会来现场进行常规的血清学检测,子样本将参与更可靠的检测
葡萄糖耐量、生物标志物和血管功能。该数据将由纵向EHR数据补充
来自参与站点和整个PCORnet。参与者将被跟踪2年。目标1将检查是否
最近服用新冠肺炎的T2D患者更有可能血糖控制更差,增加
炎症和胰岛素抵抗增加的患者比没有近期新冠肺炎的患者。目标2将检查是否
新近患有T1D并最近服用新冠肺炎的患者更有可能血糖控制更差,增加
与没有新近新冠肺炎的患者相比,炎症和β细胞功能下降更快。目标3将
评估一组糖尿病患者,检查新冠肺炎是否与血管功能恶化有关,
炎症和高凝状态增加。目标4将探索基因组/社会/环境的作用
影响炎症和代谢功能的因素。AIM 5将利用电子病历数据来探索新冠肺炎的作用
以及新冠肺炎治疗对糖尿病发展和糖尿病大流行相关结果的影响。这个
研究将由一个对新冠肺炎有丰富经验的团队领导,新冠肺炎的急性后遗症
(PASC),儿童和成人肥胖和糖尿病,流行病学研究,信息学,卫生服务
研究、基因组学、代谢组学、生理学、患者和家庭参与等领域。建议数
这项工作将提供对新冠肺炎和糖尿病之间关系的更深层次的理解,这可以支持
未来的干预措施和公共卫生方法,以改善健康。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason Perry Block其他文献
Jason Perry Block的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason Perry Block', 18)}}的其他基金
Medications and Weight Gain in PCORnet: The MedWeight Study
PCORnet 中的药物和体重增加:MedWeight 研究
- 批准号:
10348172 - 财政年份:2020
- 资助金额:
$ 599.96万 - 项目类别:
Medications and Weight Gain in PCORnet: The MedWeight Study
PCORnet 中的药物和体重增加:MedWeight 研究
- 批准号:
10560490 - 财政年份:2020
- 资助金额:
$ 599.96万 - 项目类别:
Medications and Weight Gain in PCORnet: The MedWeight Study
PCORnet 中的药物和体重增加:MedWeight 研究
- 批准号:
9885751 - 财政年份:2020
- 资助金额:
$ 599.96万 - 项目类别:
New Insights into the Federal Calorie Labeling Law
对联邦卡路里标签法的新见解
- 批准号:
10372096 - 财政年份:2018
- 资助金额:
$ 599.96万 - 项目类别:
Label to Table: New Insights into Supermarket Food Labeling
从标签到餐桌:超市食品标签的新见解
- 批准号:
10584973 - 财政年份:2018
- 资助金额:
$ 599.96万 - 项目类别:
Workplace Wellness Initiatives to Combat Obesity
对抗肥胖的工作场所健康举措
- 批准号:
8721478 - 财政年份:2013
- 资助金额:
$ 599.96万 - 项目类别:
Workplace Wellness Initiatives to Combat Obesity
对抗肥胖的工作场所健康举措
- 批准号:
8857151 - 财政年份:2013
- 资助金额:
$ 599.96万 - 项目类别:
Workplace Wellness Initiatives to Combat Obesity
对抗肥胖的工作场所健康举措
- 批准号:
8509142 - 财政年份:2013
- 资助金额:
$ 599.96万 - 项目类别:
Workplace Wellness Initiatives to Combat Obesity
对抗肥胖的工作场所健康举措
- 批准号:
9315197 - 财政年份:2013
- 资助金额:
$ 599.96万 - 项目类别:
Workplace Wellness Initiatives to Combat Obesity
对抗肥胖的工作场所健康举措
- 批准号:
9081666 - 财政年份:2013
- 资助金额:
$ 599.96万 - 项目类别:
相似海外基金
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
- 批准号:
10419967 - 财政年份:2022
- 资助金额:
$ 599.96万 - 项目类别:
A neuroimaging approach to advance mechanistic understanding of tobacco use escalation risk among young adult African American vapers
一种神经影像学方法,可促进对年轻非洲裔美国电子烟使用者烟草使用升级风险的机制理解
- 批准号:
10509308 - 财政年份:2022
- 资助金额:
$ 599.96万 - 项目类别:
Understanding social undermining of weight management behaviors in young adult African American women
了解年轻非洲裔美国女性体重管理行为的社会破坏
- 批准号:
10680412 - 财政年份:2022
- 资助金额:
$ 599.96万 - 项目类别:
Understanding social undermining of weight management behaviors in young adult African American women
了解年轻非洲裔美国女性体重管理行为的社会破坏
- 批准号:
10535890 - 财政年份:2022
- 资助金额:
$ 599.96万 - 项目类别:
A neuroimaging approach to advance mechanistic understanding of tobacco use escalation risk among young adult African American vapers
一种神经影像学方法,可促进对年轻非洲裔美国电子烟使用者烟草使用升级风险的机制理解
- 批准号:
10629374 - 财政年份:2022
- 资助金额:
$ 599.96万 - 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
- 批准号:
10592441 - 财政年份:2022
- 资助金额:
$ 599.96万 - 项目类别:
Impact of Adult Day Services on Psychosocial and Physiological Measures of Stress among African American Dementia Family Caregivers
成人日间服务对非裔美国痴呆症家庭护理人员的社会心理和生理压力测量的影响
- 批准号:
10553725 - 财政年份:2021
- 资助金额:
$ 599.96万 - 项目类别:
Voice-Activated Technology to Improve Mobility & Reduce Health Disparities: EngAGEing African American Older Adult-Care Partner Dyads
语音激活技术可提高移动性
- 批准号:
10494191 - 财政年份:2021
- 资助金额:
$ 599.96万 - 项目类别:
Impact of Adult Day Services on Psychosocial and Physiological Measures of Stress among African American Dementia Family Caregivers
成人日间服务对非裔美国痴呆症家庭护理人员的社会心理和生理压力测量的影响
- 批准号:
10328955 - 财政年份:2021
- 资助金额:
$ 599.96万 - 项目类别:
Voice-Activated Technology to Improve Mobility & Reduce Health Disparities: EngAGEing African American Older Adult-Care Partner Dyads
语音激活技术可提高移动性
- 批准号:
10437374 - 财政年份:2021
- 资助金额:
$ 599.96万 - 项目类别: